Radium-223 for the treatment of castration-resistant prostate cancer

The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in p...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Amm, Joelle, Aragon-Ching, Jeanny B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/
https://www.ncbi.nlm.nih.gov/pubmed/26056474
http://dx.doi.org/10.2147/OTT.S44291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445785/
https://www.ncbi.nlm.nih.gov/pubmed/26056474
http://dx.doi.org/10.2147/OTT.S44291

Ejemplares similares